Nisevokitug
Based on 1 Customer Validation
Nisevokitug (NIS-793) is a humanized IgG2λ monoclonal antibody and an inhibitor of the TGF-β signaling pathway. Nisevokitug blocks the binding of TGF-β to the membrane-bound TGF-βR1/TGF-βR2 receptors, inhibits both Smad-dependent and Smad-independent downstream cascade signaling, downregulates fibrosis-related genes, and reverses the TGF-β-mediated immunosuppressive microenvironment. Nisevokitug can be used in the research of diseases such as pancreatic ductal adenocarcinoma, colorectal cancer, myelofibrosis, and myelodysplastic syndrome.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.00%
- CAS. Nr.: 2649854-92-0
- Molecular Weight:146.254 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG2 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
TGF-βR2 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 lambda
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Raji cells with Nisevokitug (HY-P990009, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 2649854-92-0
-
Appearance Liquid
-
Molecular Weight 146.254 kDa
-
Color Colorless to light yellow
-
SMILES
[Nisevokitug]
-
Synonyms
NIS-793
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Guo W, et al. Targeting the TGF-β signaling pathway: an updated patent review (2021-present). Expert opinion on therapeutic patents. 2024 Mar;34(3):99-126. [Content Brief]
[2]. Watrin T, et al. The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN). Leukemia & lymphoma. 2026 Jan;67(1):17-26. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Nisevokitug
- 2649854-92-0
- NIS-793
- NIS793
- NIS 793
- TGF-beta/Smad
- TGF-β Receptor
- Transforming growth factor beta
- Transforming growth factor beta receptors
- TGF-β
- pancreatic cancer
- metastatic pancreatic ductal adenocarcinoma
- myelofibrosis
- metastatic colorectal cancer
- solid tumors
- myelodysplastic syndromes
- TGF-β signaling pathway
- Inhibitor
- inhibitor
- inhibit